comprehensive -WSS

comprehensive

author：comprehensive 2025-08-28 04:23:22 - browse：18293

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： What AstraZeneca

hotspot

WSS

House GOP plan to stem drug shortages differs from Democrats’

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Snowpack in the West is melting rapidly. Where will all that extra water go?

4 missing after record

focus

comprehensive

focus

How to save PrEP access — and even expand it

American TikTok star stuck in Dubai for months following rental car altercation

Medicare proposal to cover medical devices draws a mixed reaction

Snowpack in the West is melting rapidly. Where will all that extra water go?

Medicare details structure of new drug price negotiation program

FDA approves first blood sugar monitor without finger pricks

As demand for Covid shots wanes, Moderna seeks its next success

Where does female orgasm come from? Scientists think they know

Novavax promises a turnaround & Lilly roils the obesity market

House GOP plan to stem drug shortages differs from Democrats’

leisure time

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Men with early prostate cancer can safely opt out of treatment

Russian and Belarusian players banned from a women's tennis tournament in Prague

Campaign finance charge dropped from case against Sam Bankman

Burning questions about Delta and the next phase of the Covid pandemic

explore

hotspot

focus

entertainment